CARBOPLATIN (Kemocarb® 150mg)

Product Information

Generic Name: Carboplatin IP
Brand: Kemocarb®
Manufacturer: Fresenius Kabi India Pvt. Ltd.
Strength: 150mg/15ml (10mg/ml)
Dosage Form: Injection IP – Single Dose Vial
Administration: IV infusion after dilution only
Storage: Store at 15°C–30°C. Protect from light and avoid contact with metals.
Rx Status: Schedule H Prescription Drug – Cytotoxic Agent

Overview

Kemocarb® contains Carboplatin, a platinum-based chemotherapy medicine widely used in oncology. Oncologists prescribe Carboplatin for various solid tumors because it provides effective anti-tumor activity and a more favorable safety profile than Cisplatin. As a result, Carboplatin has become a key component of modern cancer treatment protocols worldwide.

Furthermore, healthcare professionals often combine Carboplatin with other anticancer agents to improve treatment outcomes across different cancer types.

Clinical Indications

Ovarian Cancer

Doctors commonly prescribe Carboplatin as a first-line treatment for advanced ovarian cancer. Additionally, specialists use Carboplatin with Paclitaxel as a standard treatment regimen for epithelial ovarian cancer. Physicians also recommend carboplatin-based therapy for platinum-sensitive recurrent ovarian cancer.

Non-Small Cell Lung Cancer (NSCLC)

Oncologists frequently combine Carboplatin with Paclitaxel, Gemcitabine, Pemetrexed, or Docetaxel for advanced NSCLC. Moreover, many clinicians choose Carboplatin over Cisplatin for patients with renal impairment, hearing loss, or neuropathy.

Small Cell Lung Cancer (SCLC)

Healthcare professionals often use Carboplatin together with Etoposide as a first-line treatment for both limited-stage and extensive-stage SCLC. In addition, this combination offers efficacy comparable to Cisplatin-based regimens.

Breast Cancer

Doctors use Carboplatin in selected patients with triple-negative breast cancer. Furthermore, oncologists may include it in treatment plans for BRCA-mutated breast cancers because these tumors often respond well to platinum-based therapy.

Head and Neck Cancer

Clinicians combine Carboplatin with Paclitaxel and other agents for recurrent or metastatic head and neck cancers. Consequently, it serves as an alternative for patients who cannot tolerate Cisplatin.

Testicular Cancer

Specialists prescribe single-agent Carboplatin as adjuvant therapy for Stage I seminoma. Therefore, patients may receive an effective treatment option with reduced toxicity.

Bladder Cancer

Doctors use Carboplatin-based combinations for advanced urothelial carcinoma, especially when patients are not eligible for Cisplatin therapy.

Cervical Cancer

Oncologists frequently combine Carboplatin with Paclitaxel in recurrent or metastatic cervical cancer. As a result, this regimen remains an established option in gynecologic oncology.

Mechanism of Action

Carboplatin is a second-generation platinum coordination compound. After entering the cell, it releases reactive platinum species that bind to DNA and create cross-links between DNA strands.

Consequently, cancer cells cannot replicate or transcribe their DNA effectively. The damaged cells activate cellular repair pathways; however, severe DNA damage ultimately triggers programmed cell death (apoptosis).

Moreover, Carboplatin demonstrates slower activation kinetics than Cisplatin. Therefore, it generally causes less nephrotoxicity, neurotoxicity, and ototoxicity while maintaining strong anticancer activity.

Dosing and Administration

Healthcare professionals calculate Carboplatin doses using the Calvert Formula, which considers renal function and target drug exposure.

Calvert Formula:
Dose (mg) = Target AUC × (GFR + 25)

This individualized dosing method helps clinicians achieve consistent drug exposure while reducing the risk of inappropriate dosing.

Key Clinical Benefits

• Proven efficacy across multiple solid tumors

• Better tolerability than Cisplatin in many patients

• Reduced risk of nephrotoxicity, neurotoxicity, and ototoxicity

• No requirement for aggressive hydration protocols

• Precise AUC-based dosing approach

• Excellent compatibility with combination chemotherapy regimens

• Established role in ovarian, lung, breast, and testicular cancers

• Supported by decades of clinical evidence

• Included in international oncology treatment guidelines

Product Details

• Generic: Carboplatin IP

• Brand: Kemocarb®

• Strength: 150mg/15ml (10mg/ml)

• Route: IV infusion after dilution only

• Pack Type: Single-dose vial

• Storage: 15°C–30°C, protected from light

• Manufacturer: Fresenius Kabi India Pvt. Ltd.

Regulatory Recognition

• UK MHRA Approved

• US FDA Approved

• Health Canada Approved

• Included in the WHO Essential Medicines List

• Referenced by NCCN, ESMO, and NICE oncology guidelines

• Widely used in oncology centers worldwide

Important Safety Information

Carboplatin is a prescription-only cytotoxic medicine. Therefore, trained oncology professionals should administer this product under the supervision of a qualified oncologist. Furthermore, healthcare providers must follow appropriate handling and safety procedures during preparation and administration.

Patients should use this medicine only with a valid prescription and according to professional medical guidance.

For registered healthcare professionals and licensed pharmaceutical buyers only.